Corporate News

Result of AGM

30 June 2025

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

A copy of the voting results can be found on the website later today here.

For more information visit www.genincode.com

 

Enquiries:

GENinCode Plc

www.genincode.com or via Walbrook PR

Matthew Walls, CEO


Paul Foulger, CFO

 

Cavendish Capital Markets Limited

 

Tel: +44 (0)20 7397 8900

Giles Balleny (Corporate Finance)

Nigel Birks (Life Sciences Specialist Sales)

Harriet Ward (Corporate Broking)

Dale Bellis / Michael Johnson (Sales)

 

Walbrook PR Limited

Anna Dunphy / Rachel Broad / Marcus Ulker

 

Tel: 020 7933 8780 or [email protected]  

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.